Queen Mary University of London
Population Testing for BRCA1/2 Appears Cost-Effective in Younger Canadian Women
Using simulated data for 1 million women, researchers found that population-based BRCA1/2 testing would be cost-effective, particularly in 30-year-old women.
Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D
Cold Spring Harbor spinout Envisagenics will apply its AI technology to multiomics data in pursuit of new therapies for acute myeloid leukemia and other hematopoietic cancers.
Prostate Cancer UK Funds Study of Angle's Parsortix Liquid Biopsy Test in Prostate Cancer
The trial at Barts Cancer Institute will follow 200 prostate cancer patients over five years and gauge if the CTC test can identify who will recur after surgery.
Gene Expression, Histology Reveal Clues for Targeted Rheumatoid Arthritis Treatment
Histological profiling and RNA sequencing helped identify synovial biopsy features for predicting targeted biologic therapy response in rheumatoid arthritis.
Study investigators found that patients with ctDNA-positive results after surgery were at higher risk of bladder cancer recurrence than those who were ctDNA-negative.